Intellia Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Intellia Therapeutics (NTLA) Misses Q4 EPS by 1c, Revenues Beat
February 27, 2020 7:37 AM ESTIntellia Therapeutics (NASDAQ: NTLA) reported Q4 EPS of ($0.57), $0.01 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $10.94 million versus the consensus estimate of $9.94 million.
In 2019, we advanced our full-spectrum strategy, guiding both our in vivo and ex vivo lead... More
